Latest International Expansion News

Hydrocarbon Dynamics Limited reported ongoing sales and expanded trials of its HCD Multi-Flow product worldwide, alongside plans for a fully underwritten rights issue to bolster its financial position.

OpenLearning Limited reported a robust Q2 FY25 with 22% year-on-year SaaS ARR growth to $2.65 million, driven by significant multi-year contract wins and expanding global customer base. The company’s AI-powered LMS strategy is delivering larger deals and improved cash flow metrics.

Spacetalk Ltd reports robust growth in paid mobile subscribers and recurring revenue for Q4 FY25, supported by strategic capital raises and international expansion.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

Advanced Braking Technology Ltd (ABT) posted a robust FY25 with sales up 27% and underlying profits nearly doubling, driven by strong international demand and innovation milestones.

Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Anagenics Limited reports improved operating cash flow and strong sales from its Bouf Haircare brand, while exploring international expansion and a key licensing deal.

Bubs Australia has appointed Joe Coote as its new CEO, bringing extensive international FMCG and dairy leadership to spearhead its global growth ambitions in infant nutrition.

International Graphite Limited (ASX – IG6) has had its trading suspension lifted following the announcement of a new agreement to develop a graphite processing facility in Europe.

PainChek Limited has raised A$7.5 million through a strongly supported placement to accelerate its US market entry following anticipated FDA clearance and expand its innovative AI pain assessment technology internationally.

Compumedics has secured two significant four-year distribution agreements in China worth A$24.4 million, reinforcing its strategic foothold in Asia with committed annual growth of at least 10%.